Enlivex Therapeutics Ltd. Files 6-K Report
Ticker: ENLV · Form: 6-K · Filed: Sep 25, 2025 · CIK: 1596812
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, company-update
Related Tickers: ENLV
TL;DR
Enlivex Therapeutics (ENLV) filed a 6-K on 9/25/25, updating its foreign private issuer status and address in Israel.
AI Summary
Enlivex Therapeutics Ltd. filed a Form 6-K on September 25, 2025, reporting on its activities as a foreign private issuer. The filing indicates the company's principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel. Enlivex Therapeutics Ltd. previously operated under the names Bioblast Pharma Ltd. and BIO BLAST PHARMA LTD.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Enlivex Therapeutics' status and operations as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine administrative filing (6-K) and does not contain new material financial or operational information that would typically increase risk.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Filer of the report
- Bioblast Pharma Ltd. (company) — Former company name
- BIO BLAST PHARMA LTD. (company) — Former company name
- September 25, 2025 (date) — Filing date
- 14 Einstein Street, Nes Ziona, Israel (location) — Principal executive offices
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that provides information which the issuer makes or is required to make public pursuant to the laws of the issuer's home country or jurisdiction, or which it furnishes or makes public to its security holders.
When was Enlivex Therapeutics Ltd. previously known as Bioblast Pharma Ltd.?
The company's name change from Bioblast Pharma Ltd. to Enlivex Therapeutics Ltd. occurred on September 19, 2016.
Where are Enlivex Therapeutics Ltd.'s principal executive offices located?
The company's principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel, 7403618.
Does Enlivex Therapeutics Ltd. file annual reports under Form 20-F?
Yes, the filing indicates that the registrant files annual reports under cover of Form 20-F.
What is the SEC file number for Enlivex Therapeutics Ltd.?
The SEC file number for Enlivex Therapeutics Ltd. is 001-36578.
Filing Stats: 284 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2025-09-25 16:30:44
Filing Documents
- ea0258628-01.htm (6-K) — 29KB
- ea025862801ex99-1_enlivex.htm (EX-99.1) — 172KB
- ea025862801ex99-2_enlivex.htm (EX-99.2) — 8KB
- tproxy_001.jpg (GRAPHIC) — 1070KB
- tproxy_002.jpg (GRAPHIC) — 795KB
- 0001213900-25-091674.txt ( ) — 2779KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   Enlivex Therapeutics Ltd.     (Registrant)     By:   /s/ Oren Hershkovitz     Name:   Oren Hershkovitz     Title:   Chief Executive Officer Date: September 25, 2025 2